You are here

IFG::OT::IFG: At-Home Prescription Drug Disposal System N43DA-13-4421. Period o

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N43DA130016
Agency Tracking Number: N43DA130016
Amount: $149,799.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDA
Solicitation Number: N/A
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
GINER, INC. 89 RUMFORD AVENUE
NEWTON, MA 02466-1311
United States
DUNS: 066594979
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 BADAWI DWEIK
 (781) 529-0500
 BDWEIK@GINERINC.COM
Business Contact
 BADAWI DWEIK
Phone: (781) 529-0500
Email: BDWEIK@GINERINC.COM
Research Institution
N/A
Abstract

Objective: Demonstrate effectiveness of a safe, immediate, cost-effective, ecological, and user-friendly system that enables at-home deactivation and disposal of psychoactive prescription pharmaceuticals. Giner, Inc. proposes to develop a miniaturized electrolytic mixed-oxidant (MOX) system to safely destroy psychoactive pharmaceuticals in solid, liquid or patch form. The proposed system is designed to temporarily attach to a standard household faucet to eliminate need for extra equipment and to achieve size, performance and safety advantages over existing technologies. Phase I will assess overall feasibility of concept by focusing on design of MOX reactor and identifying requirements to inactivate selection of highly used pharmaceutical drugs. Phase I focuson following Specific Aims: 1. Design, Fabricate and Assemble BDD/MOX System Components. Focus on development/fabrication of compact and functional electrolytic MOX reactor unit by designing electrode structure and assembling necessary components. 2.Characterize Key Process Variables and Parameters. Process variables and parameters will be identified and optimized for sufficient electro-generation of mixed oxidants to inactivate select pharmaceutical products. 3. Demonstrate Suitable Performance of the System on Select Pharmaceuticals. Performance of proposed system will be assessed using psychoactive pharmaceutical products (Vicodin, Xanax, and Zoloft) selected for their frequency of prescription, treatment class and range of chemical structures. 4.Product Use, Placement, and Safety Evaluation. Product evaluated for ease of operation and target user safety from harmful exposure throughout entire deactivation process. Aim will also assess different ways product will be distributed to consumers. 5. Preliminary Design for Phase II Prototype. Focus on designing device prototype for Phase II and product cost analyses to demonstrate feasibility of proposed deactivation device for Phase II scale-up. PUBLIC HEALTH RELEVANCE

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government